{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=19",
    "query": {
      "condition": "Sars-CoV2",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 1235,
    "total_pages": 124,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sars-CoV2&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T05:49:33.292Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05780281",
      "title": "VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "VIR-7831",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 367,
      "start_date": "2020-12-16",
      "completion_date": "2022-10-04",
      "has_results": true,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 74,
      "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05780281"
    },
    {
      "nct_id": "NCT04661839",
      "title": "A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "COVID-HIGIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-12-24",
      "completion_date": "2021-07-27",
      "has_results": true,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04661839"
    },
    {
      "nct_id": "NCT06928272",
      "title": "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "Pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo for pirfenidone",
          "type": "DRUG"
        },
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo for upadacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Douglas D. Fraser",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 348,
      "start_date": "2025-09-10",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06928272"
    },
    {
      "nct_id": "NCT05799495",
      "title": "A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "PF-07817883",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 240,
      "start_date": "2023-05-23",
      "completion_date": "2023-10-11",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 53,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05799495"
    },
    {
      "nct_id": "NCT04405739",
      "title": "The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "EIDD-2801",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ridgeback Biotherapeutics, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-16",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405739"
    },
    {
      "nct_id": "NCT04401579",
      "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1033,
      "start_date": "2020-05-08",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2022-03-14",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401579"
    },
    {
      "nct_id": "NCT04415151",
      "title": "Tofacitinib for Treatment of Moderate COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Pneumonia"
      ],
      "interventions": [
        {
          "name": "Tofacitinib 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-10-14",
      "completion_date": "2021-02-28",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04415151"
    },
    {
      "nct_id": "NCT04402957",
      "title": "LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Severe Acute Respiratory Syndrome",
        "Sars-CoV2",
        "Acute Kidney Injury",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "LSALT peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arch Biopartners Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 61,
      "start_date": "2020-10-14",
      "completion_date": "2022-06-02",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402957"
    },
    {
      "nct_id": "NCT05279365",
      "title": "PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS CoV 2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Pfizer/BioNTech (BNT162b2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Moderna",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DHR Health Institute for Research and Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2021-07-30",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 4,
      "location_summary": "Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas",
      "locations": [
        {
          "city": "Brownsville",
          "state": "Texas"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Edinburg",
          "state": "Texas"
        },
        {
          "city": "Rio Grande City",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05279365"
    },
    {
      "nct_id": "NCT04332107",
      "title": "Azithromycin for COVID-19 Treatment in Outpatients Nationwide",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Azithromycin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas M. Lietman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2020-05-22",
      "completion_date": "2021-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-02",
      "last_synced_at": "2026-10-23T05:49:33.292Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04332107"
    }
  ]
}